BRIEF-Catabasis Pharmaceuticals reports positive DMD drug data
October 04, 2017 at 11:11 AM EDT
* Catabasis Pharmaceuticals reports positive results from open-label extension of phase 2 MoveDMD trial evaluating edasalonexent in duchenne muscular dystrophy
